Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines

Klin Padiatr. 2015 May;227(3):123-30. doi: 10.1055/s-0034-1398628. Epub 2015 May 18.

Abstract

Background: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy. In a former study we detected that the valosin-containing protein (VCP, cdc48), a member of the ubiquitin proteasome degradation system (UPS), is altered in gc-resistant leukemic cells suggesting that the associated pathways might be involved in chemotherapy resistance in childhood ALL.

Methods: Human B-cell precursor leukemia cell lines, gc-resistant MHH-cALL-2 and gc-sensitive MHH-cALL-3, were treated with prednisolone and various concentrations of bortezomib. Viability and apoptosis rates were determined.

Results: Both cell lines showed a dose-dependent increase in caspase activity after bortezomib single treatment. The gc-sensitive cells showed an additive effect after combined treatment with prednisolone and bortezomib. In contrast, both cell lines showed a reduced viability and enhanced propidium iodide positivity after combined treatment as determined by flow cytometry. Western blot analyses of poly-(ADP-ribose) polymerase 1 (PARP-1) suggested that combined treatment promote necrotic cleavage of PARP-1 in gc-resistant cells. Furthermore, after prednisolone treatment the UPS associated proteins VCP and NFκB-inhibitor IκBα were differentially modulated in gc-resistant cells.

Conclusions: The proteasome inhibitor bortezomib seems to sensitize gc-resistant childhood ALL cells for prednisolone-induced cell death.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / genetics
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Bortezomib / pharmacology*
  • Cell Cycle Proteins / genetics
  • Cell Death / drug effects
  • Cell Line, Tumor / drug effects
  • Cell Proliferation
  • Cell Survival / drug effects*
  • Child
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm* / genetics
  • Flow Cytometry
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glucocorticoids / pharmacology*
  • Humans
  • I-kappa B Proteins / genetics
  • NF-KappaB Inhibitor alpha
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Prednisolone / pharmacology
  • Valosin Containing Protein

Substances

  • Cell Cycle Proteins
  • Glucocorticoids
  • I-kappa B Proteins
  • NFKBIA protein, human
  • NF-KappaB Inhibitor alpha
  • Bortezomib
  • Prednisolone
  • Adenosine Triphosphatases
  • VCP protein, human
  • Valosin Containing Protein